Zim Laboratories has filed the regulatory dossier for approval of Rizatriptan orally dissolving film in Europe. Rizatriptan orally dissolving film is a product developed using its Thinoral technology which yields instantly wettable, rapidly dissolving, and stable films.
The product is used in the treatment of migraine which is invariably associated with symptoms like nausea and vomiting. The submission of the Rizatriptan orally dissolving film MAA represents a critical milestone for ZIM and for European patients suffering from Migraine.
Zim Laboratories has established itself as one of the preferred healthcare solution providers in the field of New Drug Delivery Systems (NDDS).
